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Objective: The aim of this study is to evaluate serum ferritin levels and polycystic ovary syndrome
(PCOS)-related complications in obese and nonobese women.
Materials and methods: This retrospective study included 539 (286 with PCOS and 253 without PCOS).
Results: Serum ferritin correlated with menstrual cycle length, sex hormone-binding globulin, total
testosterone, androstenedione, triglyceride, and total cholesterol in both obese and nonobese women.
Obese women with high ferritin levels exhibited higher insulin resistance, impaired glucose tolerance,
and liver enzymes (glutamic oxaloacetic transaminase, glutamic pyruvic transaminase) than obese
women with low ferritin levels. However, among nonobese women, insulin resistance and risk of dia-
betes were not signiﬁcantly different between the high and low ferritin groups. Independent of obesity,
hypertriglyceridemia was the major metabolic disturbance observed in women with elevated serum
ferritin levels.
Conclusion: Elevated serum ferritin levels are associated with increased insulin resistance and risk of
diabetes in obese women but not in nonobese women. However, higher serum ferritin levels were
correlated with a greater risk of hyperglyceridemia in both obese and nonobese women. Therefore,
hypertriglyceridemia in women with PCOS might be associated with iron metabolism.
Copyright © 2015, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Ferritin is a ubiquitous intracellular protein that is essential for
the regulation of iron homeostasis. The serum ferritin level is
widely used as a clinical biomarker to estimate body iron status.
Iron is a strong pro-oxidant, and high body iron levels are associ-
ated with an increased level of oxidative stress, which may elevate
the risk of type 2 diabetes [1]. Mildly elevated body iron stores are
associated with statistically signiﬁcant increases in glucose ho-
meostasis indices [2,3]. Furthermore, patients with elevated iron
stores present both insulin resistance and metabolic alterationsand Gynaecology, Wan Fang




bstetrics & Gynecology. Publishedthat put them at increased risk for cardiovascular disease (CVD)
[4,5].
Polycystic ovary syndrome (PCOS) is an endocrine disorder that
affects 6e7% of premenopausal women [6]. PCOS is clinically
diagnosed by hyperandrogenism and chronic anovulation; how-
ever, its morbidity includes insulin resistance, type 2 diabetes
mellitus, hypertension, cardiovascular disease, and infertility [7].
Increased serum ferritin levels are frequently observed in women
with PCOS [8]. An excess of androgen and menstrual dysfunction
are correlated with ferritin levels in premenopausal women [9].
Factors contributing to potential iron overload inwomenwith PCOS
include the iron-sparing effect of chronic menstrual dysfunction,
insulin resistance, and a decrease in hepcidin, which leads to
increased iron absorption [10].
Serum ferritin concentrations differ signiﬁcantly according to
sex, body status, and ethnicity [3,11,12]. A growing number of
studies suggest a potential link between obesity and altered ironby Elsevier Taiwan LLC. All rights reserved.
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ferritin levels and certain diagnostic components of metabolic
syndrome might be different in men and women [12]. Menstru-
ating women are at risk for iron deﬁciency; however, obese
menstruating women are at low risk of depleting their iron stores
[13]. Recently, we reported that obesity is the main factor associ-
ated with the prevalence of insulin resistance, impaired glucose
tolerance, and metabolic syndrome in women with PCOS [14,15].
The correlation between serum ferritin levels and metabolic com-
ponents in obese and nonobese women is not well understood.
Therefore, we conducted this retrospective study to evaluate the
relationship between ferritin levels, insulin resistance, metabolic
disturbances, and PCOS-related syndrome among obese and non-
obese women.Materials and methods
This study was approved by the Taipei Medical University Joint
Institutional Review Board (Taipei, Taiwan), and registered in the
Protocol Registration System of ClinicalTrials.gov (identiﬁer
NCT01600833).
We retrospectively reviewed the medical records of female pa-
tients who visited our clinic from January 1, 2008 to November 30,
2011. The chief complaints of these patients included menstrual
disturbance, dysmenorrhea, infertility, and acne/hirsutism. The
following were excluded: (1) womenwho had been diagnosedwith
congenital adrenal hyperplasia, androgen-secreting tumor, Cush-
ing's syndrome, or disorders of the uterus; (2) women who expe-
riencedmenarche <3years before the evaluation or thosewhowere
older than 46 years; and (3) women who received hormones or
drugs for major medical diseases. A total of 639 women were
initially screened. One hundred women were excluded due to
hyperprolactinemia (n ¼ 62), ovarian failure (n ¼ 18), and insufﬁ-
cient data (n¼ 20). Overall, 539womenwere included in this study.
Medical histories included detailed menstrual and medical/
surgical records as well as anthropometric measurements.
Biochemical hyperandrogenemia was deﬁned as total serum
testosterone0.8 ng/mL (normal range for female adult 0.1e0.8 ng/
mL), androstenedione  2.99 ng/dL (normal range for female adult
0.10e2.99 ng/mL), or  275 mg/L [16]. Hirsutism was deﬁned as a
modiﬁed FerrimaneGallwey score 6. The number of menstrualTable 1
Correlation of ferritin with clinical and biochemical insulin resistance and metabolic syn
Total (n ¼ 539)
Correlation p
Parameters correlated with ferritin both in obese and nonobese women
Menstrual cycle length 0.320 <0.001*
Sex hormone-binding globulin 0.249 <0.001*




Parameters correlated with ferritin both in obese but not nonobese women
Fasting insulin 0.257 <0.001*
Fasting glucose 0.270 <0.001*
HOMA-IR 0.329 <0.001*
Hemoglobin A1c 0.284 <0.001*
GOT 0.561 <0.001*
High-density lipoprotein 0.196 <0.001*
Body mass index 0.271 <0.001*
High-sensitivity C-reactive protein 0.248 <0.001*
Systolic pressure 0.210 <0.001*
Diastolic pressure 0.220 <0.001*
*p < 0.05.
GOT ¼ glutamic oxaloacetic transaminase; HOMA-IR ¼ homeostasis model assessment icycles during the previous year was recorded. Menstrual interval
was deﬁned as 365 divided by the number of menstrual cycles in
the previous year. Oligomenorrhea/amenorrhea was deﬁned as a
menstrual interval of >35 days or fewer than 10 menstruation cy-
cles in the previous year. Obesity was deﬁned as having a body
mass index 25 kg/m2. The deﬁnition of polycystic ovaries was
previously described [17].
PCOSwas diagnosed according to the Androgen Excess and PCOS
Society criteria for the polycystic ovary syndrome [18], which
require the presence of hyperandrogenism and ovarian dysfunction.
Serum ferritin levels were obtained in all 539 women, and the
median level was 45.5 ng/mL. To evaluate further the clinical and
biochemical characteristics of women with different levels of
serum ferritin, the study cases were classiﬁed into the following
subgroups: high ferritin group (ferritin 45.5 ng/mL, n ¼ 270) and
low ferritin group (ferritin <45.5 ng/mL, n ¼ 269).
Metabolic syndrome (2005 National Cholesterol Education
Program Adult Treatment Panel III) was deﬁned as the presence of
at least three of the following criteria: abdominal obesity, hyper-
triglyceridemia (triglycerides  150 mg/dL), serum high-density
lipoprotein <50 mg/dL, hypertension, and fasting plasma
glucose  100 mg/dL.
Statistical analysis
Statistical analysis was performed using SPSS 13.0 for Windows
(SPSS, Inc., Chicago, IL, USA). We evaluated the correlation between
serum ferritin levels and related parameters with Pearson's corre-
lation coefﬁcients using the two-tailed method (Table 1). In Table 2,
data are presented as the means ± standard deviation. We used the
Chi-square test and Fisher exact test to compare categorical vari-
ables, and ANOVA was used to compare continuous variables. Dif-
ferences between the groups were considered to be signiﬁcant at
p < 0.05.
Results
Table 1 illustrates the correlation between serum ferritin levels
and related parameters in all, obese, and nonobese women. Serum
ferritin correlated with menstrual cycle length, sex hormone-
binding globulin, total testosterone, androstenedione, triglyceride,drome (n ¼ 539).
Obese (n ¼ 233) Nonobese (n ¼ 306)
Correlation p Correlation p
0.378 <0.001* 0.124 0.031*
0.192 0.003* 0.197 0.001*
0.151 0.021* 0.224 <0.001*
0.164 0.012* 0.257 <0.001*
0.158 0.016* 0.129 0.026*
0.264 <0.001* 0.324 <0.001*
0.233 0.002* 0.009 0.872
0.258 <0.001* 0.092 0.115
0.306 <0.001* 0.043 0.455
0.258 0.001* 0.068 0.289
0.621 <0.001* 0.048 0.411
0.137 0.037* 0.045 0.437
0.149 0.023* 0.044 0.442
0.229 <0.001* 0.074 0.202
0.167 0.013* 0.049 0.397
0.175 0.009* 0.040 0.497
nsulin resistance index.
Table 2
A comparison of biochemical characteristics of obese and non-obese women with high and low ferritin.
Obese Non-obese
Low ferritina High ferritina p Low ferritina High ferritina p
Case number 89 144 180 126
Ferritin (ng/mL) 25.1 ± 12.5 117.4 ± 99.2 <0.001* 25.6 ± 12.1 82.0 ± 38.8 <0.001*
Age (y/o) 29.0 ± 6.7 27.8 ± 6.5 0.180 27.6 ± 6.3 26.5 ± 6.6 0.143
Menstrual cycle length (days) 64.1 ± 64.1 113.4 ± 116.0 <0.001* 61.1 ± 66.5 83.9 ± 81.4 0.008*
BMIa (kg/m2) 31.3 ± 5.2 31.3 ± 4.8 0.951 20.5 ± 2.1 20.6 ± 2.0 0.579
PCOS 44% 62% 0.007* 44% 63% 0.001*
Hyperandrogenism 53% 69% 0.014* 55% 69% 0.013*
Polycystic ovaries 57% 63% 0.433 56% 58% 0.752
Oligo/amenorrhea 66% 76% 0.094 52% 74% <0.001*
SHBGa (nmol/L) 32.0 ± 17.2 23.0 ± 12.9 <0.001* 58.9 ± 28.8 47.4 ± 26.9 <0.001*
hsCRPa (mg/dL) 0.30 ± 0.31 0.47 ± 0.44 0.012* 0.10 ± 0.22 0.17 ± 0.37 0.051
Systolic pressure (mmHg) 120.6 ± 15.5 125.4 ± 18.7 0.051 106.8 ± 13.7 104.9 ± 11.9 0.225
Diastolic pressure (mmHg) 83.6 ± 11.8 87.1 ± 14.2 0.062 71.9 ± 10.0 71.4 ± 9.9 0.688
Anthropometric measurements
Weight (kg) 81.8 ± 15.1 81.3 ± 13.0 0.766 52.5 ± 6.0 52.9 ± 6.3 0.496
Height (cm) 161.0 ± 5.3 161.0 ± 5.7 0.444 160.0 ± 4.7 160.0 ± 5.7 0.908
Waist (cm) 96.6 ± 12.6 98.2 ± 12.0 0.331 73.2 ± 6.9 73.8 ± 7.1 0.446
Hip (cm) 111.0 ± 9.1 109.3 ± 8.7 0.154 91.7 ± 5.3 92.0 ± 6.3 0.685
Waist to hip ratio 0.87 ± 0.08 0.90 ± 0.08 0.007* 0.80 ± 0.08 0.80 ± 0.08 0.591
Androgens
Total testosterone (ng/mL) 0.64 ± 0.25 0.76 ± 0.33 0.003* 0.51 ± 0.24 0.62 ± 0.30 0.001*
Androstenedione (ng/mL) 2.5 ± 1.3 2.9 ± 1.3 0.017* 2.4 ± 1.1 3.0 ± 1.4 <0.001*
Free androgen indexa 10.1 ± 9.3 15.0 ± 10.2 <0.001* 3.9 ± 3.1 6.2 ± 5.2 <0.001*
DHEASa (ng/dL) 185 ± 82 210 ± 118 0.076 186 ± 99 195 ± 101 0.448
17-OH PRGa (ng/dL) 0.9 ± 0.6 1.1 ± 0.7 0.131 1.1 ± 0.9 1.3 ± 1.0 0.283
Insulin sensitivity and glucose tolerance
Fasting insulin (uIU/mL) 16.1 ± 11.7 21.9 ± 18.7 0.010* 8.8 ± 10.8 8.5 ± 4.5 0.705
Fasting glucose (mg/dL) 94.0 ± 10.0 101.1 ± 27.5 0.020* 87.7 ± 7.3 89.4 ± 16.3 0.235
2-hour glucose (mg/dL) 116.0 ± 33.9 148.8 ± 64.0 <0.001* 98.0 ± 23.9 100.8 ± 33.7 0.404
Hemoglobin A1c, % 5.5 ± 0.3 5.9 ± 1.0 0.004* 5.4 ± 0.3 5.4 ± 0.4 0.646
HOMA-IRa 3.8 ± 3.0 5.7 ± 5.5 0.004* 1.9 ± 2.1 1.9 ± 1.1 0.866
Impaired glucose tolerance, % 16% 32% 0.009* 6% 5% 0.603
Diabetes mellitus, % 3% 16% 0.003* 1% 2% 0.378
Hormonal components
LH (mIU/mL) 7.8 ± 6.1 9.2 ± 8.8 0.215 10.3 ± 13.3 11.2 ± 8.3 0.487
FSH (mIU/mL) 5.9 ± 2.1 5.8 ± 1.7 0.831 6.5 ± 2.4 7.0 ± 2.2 0.081
TSH (mIU/mL) 1.9 ± 1.2 2.2 ± 1.3 0.121 1.8 ± 1.1 2.0 ± 1.2 0.311
Prolactin (mIU/mL) 14.1 ± 5.1 13.3 ± 5.2 0.227 14.2 ± 5.3 14.2 ± 5.4 0.999
Liver function
GOTa (IU/I) 24.0 ± 10.1 32.0 ± 20.9 0.001* 20.5 ± 6.9 20.5 ± 5.6 0.938
GPTa (IU/I) 24.0 ± 13.9 41.5 ± 34.5 <0.001* 16.7 ± 9.7 17.9 ± 9.3 0.291
Lipid proﬁles and blood pressure
Cholesterol (mg/dL) 184.4 ± 32.4 194.7 ± 39.3 0.039* 179.0 ± 33.1 186.0 ± 32.3 0.069
Triglycerides (mg/dL) 103.6 ± 60.5 142.6 ± 125.3 0.006* 60.6 ± 28.0 78.6 ± 71.0 0.003*
HDLa (mg/dL) 44.8 ± 12.5 42.6 ± 11.3 0.156 60.0 ± 14.8 59.8 ± 15.1 0.914
LDLa (mg/dL) 118.7 ± 26.5 125.7 ± 32.0 0.087 100.0 ± 28.6 105.2 ± 28.4 0.118
Metabolism
Metabolic syndrome 43% 66% <0.001* 3% 6% 0.337
Hypertension 47% 53% 0.354 11% 12% 0.695
HDLa < 50 mg/dl 74% 83% 0.091 25% 26% 0.914
Triglycerides  150 mg/dL 12% 32% 0.001* 1% 6% 0.012*
Waist > 80 cm 94% 96% 0.622 19% 19% 0.964
FPGa  100 mg/dL 19% 36% 0.007* 5% 7% 0.331
Note: Data are either mean ± SD or are percentage; * p < 0.05.
a Low ferritin ¼ serum ferritin level < 45.5 ng/mL; high ferritin ¼ serum ferritin level 45.5 ng/mL; BMI ¼ body mass index; PCOS ¼ polycystic ovary syndrome;
PCOM¼ polycystic ovarymorphology; SHBG¼ sex hormone-binding globulin; hsCRP¼ high-sensitivity C-reactive protein; free androgen index (FAI)¼ T (nmol/l) 100/SHBG
(nmol); DHEA-S¼ dehydroepiandrosterone sulfate; 17-OH PRG¼ 17-a-OH progesterone; HOMA-IR¼ homeostasis model assessment insulin resistance index; GOT¼ glutamic
oxaloacetic transaminase; GPT ¼ glutamic pyruvic transaminase; HDL ¼ high-density lipoprotein; LDL ¼ low-density lipoprotein; FPG ¼ fasting plasma glucose.
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insulin, fasting glucose, glycated hemoglobin, homeostasis model
assessment insulin resistance index, glutamic oxaloacetic trans-
aminase, and high-density lipoprotein were correlated with serum
ferritin levels among obese women, but not among nonobese
women. However, a strong correlation between serum ferritin
levels and triglycerides was observed in both obese and nonobese
women. Obese women had signiﬁcantly higher serum ferritin
(82.1 ± 90.3 vs. 48.8 ± 38.3; p < 0.001) and hs-CRP (0.39 ± 0.41 vs.
0.13 ± 0.30; p < 0.001) levels than nonobese women.Table 2 compares the clinical and biochemical characteristics of
women with low and high ferritin level in the obese and nonobese
subgroups. Women with high ferritin levels had a greater risk of
PCOS and hyperandrogenism than women with low ferritin levels.
Furthermore, womenwith high ferritin levels had longermenstrual
interval, lower sex hormone-binding globulin, and higher serum
androgens and triglycerides than womenwith low ferritin levels in
both obese and nonobese women. Obese women with high ferritin
levels had higher insulin resistance, impaired glucose tolerance,
and liver enzymes than obese women with low ferritin levels.
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bolic disturbances were not signiﬁcantly different between the
high and low ferritin groups.
Discussion
Ferritin is the cellular storage protein for iron, and reduced
serum ferritin provides unequivocal evidence of diminished iron
stores. In women, a serum ferritin concentration 150 ng/mL is
usually deﬁned as hyperferritinemia [19], but increased serum
ferritin concentrations in nonpathological conditions, reﬂecting
subclinical iron overload, are associated with insulin resistance and
an increased risk of type 2 diabetes mellitus [3]. This is probably
due to the fact that the normal ranges of serum ferritin are too
wide, and the criteria for iron overload are too high [20]. To study
the effect of serum ferritin levels in this study, women were clas-
siﬁed into high and low serum ferritin groups according to the
median ferritin levels in our samples.
Obese women tended to have higher hemoglobin and ferritin
concentrations and lower transferrin saturation compared with the
nonobese women [11,21]. Previous studies have reported that
ferritin is elevated in inﬂammatory conditions, even in the presence
of true iron deﬁciency [22]. To consider whether body status may
impact the pathological effects of ferritin, we separately analyzed
obese and nonobese women. Although high serum ferritin was
associated with insulin resistance and metabolic disturbance in
obese women, we did not observe any association between serum
ferritin levels and parameters of insulin resistance in nonobese
women. This result could explain why a study of nonobese Korean
women determined no signiﬁcant differences in the homeostasis
model assessment insulin resistance index in various serum ferritin
levels [23].
Prolonged menstrual cycle length was correlated with higher
serum ferritin levels. Factors contributing to potential iron overload
might result from reduced menstrual losses, secondary to oligo- or
amenorrhea, or from hyperinsulinism, secondary to insulin resis-
tance, because insulin favors the intestinal absorption and the tis-
sue deposition of iron [10]. Regular blood loss during menstruation
is a physical characteristic of reproductive-aged women. Serum
ferritin concentration is directly related to reticuloendothelial iron
stores, and normally, 1 mg/L of serum ferritin corresponds to
approximately 8 mg of storage iron [22]. Our results indicate that
prolonged menstrual cycle length is an important factor for iron
overload resulting from reduced menstrual losses in reproductive-
aged women. Furthermore, serum ferritin levels and disturbances
in insulin resistance were observed in obese women, but not
nonobese women. However, the pathogenesis of increased iron
stores on insulin resistance among obese and nonobese premeno-
pausal women might be different. Increased iron stores in obese
women could be a consequence of insulin resistance [24], whereas
reduced menstrual losses inwomenwith oligomenorrhea might be
a major factor contributing to increased iron stores in nonobese
women.
Independent of obesity, women with higher ferritin levels have
a greater risk of hypertriglyceridemia. The mechanism underlying
increased serum ferritin hypertriglyceridemia is not clear. Iron
accumulation results from the downregulation of the iron-export
protein, ferroportin-1, which increases the levels of cytokines,
such as tumor necrosis factor-a. Tumor necrosis factor-a is involved
in hyperferritinemia, and the observed high ferritin concentration
could be an inﬂammatory manifestation. A study by Mateo-Gallego
et al [25] suggested that genetic mechanisms underlying hyper-
triglyceridemia also favor iron overload. An elevated triglyceride
level is a predictor of cardiovascular disease (CVD) in women
[25e27]. The American Heart Association recently issued ascientiﬁc statement that enforced the pivotal role of triglycerides in
lipid metabolism, reafﬁrming that triglycerides are not directly
atherogenic, but represent an important biomarker of CVD risk
[28]. In terms of metabolic syndrome, the risk of hyper-
triglyceridemia was signiﬁcantly increased in women with high
ferritin levels. A previous study reported that elevated serum
ferritin levels may be employed as a marker of metabolic syndrome
in nonobese women [23]; however, the association between serum
triglycerides and ferritin might be used to understand metabolic
disturbances in nonobese women with elevated ferritin levels.
Because serum ferritin levels might be a good indicator of men-
strual pattern and metabolic disturbance, measuring serum ferritin
levels might be useful for evaluating cardiovascular risk in women
of reproductive age.
There are several limitations to our study. Serum ferritin con-
centrations differ signiﬁcantly according to sex, body status, and
ethnicity. Therefore, we classiﬁed our population into two sub-
groups (high and low ferritin groups) based on the median
(45.5 ng/mL) of our data. The cut-off points employed in this study
to determine higher and lower ferritin levels might not apply to
other studies. This is a cross-sectional, retrospective study, and the
participants were Taiwanese patients who visited our reproductive
endocrine outpatient department during a ﬁxed interval. The
average body weight of Taiwanese women is lower than that of
western women; therefore, our results should be applied to the
general population with caution.
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